Global Allergic Conjunctivitis Market Report to 2031 - Featuring AbbVie, Ajanta Pharma, Akron Operating and Bausch Health Companies Among Others


Dublin, Jan. 04, 2023 (GLOBE NEWSWIRE) -- The "Allergic Conjunctivitis Market By Drug Class, By Disease Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

The global allergic conjunctivitis market was valued at $1,937.99 million in 2021, and is estimated to reach $2,954.2 million by 2031, growing at a CAGR of 4.28%% from 2022 to 2031.

An allergic reaction to things such as pollen, mold, or spores can result in an eye inflammation known as allergic conjunctivitis. The conjunctiva is a membrane that covers the interior of the eyelids and the surface of the eyeball. Allergens can irritate the conjunctiva, especially during the hay fever season. Conjunctivitis due to an allergy is extremely prevalent. It is a response by individual's body to chemicals that it seems to be potentially dangerous.

Conjunctivitis caused by allergens is one of the most commonly occurring allergies. According to the Asthma and Allergy Foundation of America, allergies run in families and impact 30% of adults and 40% of children. Common signs of allergic conjunctivitis include red, watery, burning, and itchy eyes. It's also possible to have puffy eyes when one first wake up in the morning.

The major factors that drive the growth of the allergic conjunctivitis market are increase in patient population suffering from ocular allergies. According to National Centre of medicine allergic conjunctivitis or conjunctival symptoms are present in 30-71% of patients with allergic rhinitis as many people are suffering from allergic conjunctivitis demand for drugs increases.

In addition, many key market players are focusing on R&D activities to develop new drugs for the treatment of ocular allergies is a key trend of the market, which is expected to fuel the growth in the forecast period.

Furthermore, poor hygienic practices such as touching eyes with unclean hands, using contaminated makeup & lotions causes ocular allergy, which is anticipated to drive the market growth in the near future. Rise in prevalence of sexually transmitted diseases tends to drive the market growth. The most prevalent STIs are chlamydia and gonorrhoea, and both can result in conjunctivitis.

Either directly through sexual fluids like semen or when infected individuals rub their eyes after contacting infected genital areas, which are the two ways the illness enters the eye. Thus, such high number of cases are expected to boost the allergic conjunctivitis procedures.

However, unfavorable reimbursements scenarios and lack of awareness of ocular allergies are expected to hinder the growth of the market. Conversely, rapid rise in urbanization leads to more exposure to chemicals and pollutants in both developed and developing countries, which is expected to provide a great opportunity for the investors to invest in the market.

The global allergic conjunctivitis market is segmented on the basis of drug class, disease type, distribution channel, and region. On the basis of drug class, the market is categorized into antihistamines & mast cell, corticosteroids, and others. By disease type, it is divided into seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC).

The seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) each are further sub segmented by age group into adult and pediatric. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are AbbVie Inc., Ajanta Pharma Limited, Akron Operating Company LLC, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc , Cipla, Inc., Grevis Pharmaceutical Private Limited , Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services Inc., Novartis AG, Ocular Therapeutics, Inc., Santen Pharmaceuticals Co. Ltd., Spectra Vision Care Pvt. Ltd, Sun Pharmaceuticals Industries Ltd andTeva Pharmaceutical Industries Ltd.

Key Benefits

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the allergic conjunctivitis market analysis from 2021 to 2031 to identify the prevailing allergic conjunctivitis market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the allergic conjunctivitis market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global allergic conjunctivitis market trends, key players, market segments, application areas, and market growth strategies.
Report AttributeDetails
No. of Pages303
Forecast Period2021 - 2031
Estimated Market Value (USD) in 2021$1937.99 million
Forecasted Market Value (USD) by 2031$2954.2 million
Compound Annual Growth Rate4.3%
Regions CoveredGlobal

Key Topics Covered:

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Antihistamines & Mast Cell Stabilizers
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Corticosteroids
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country

CHAPTER 5: ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Seasonal Allergic Conjunctivitis (SAC)
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Perennial Allergic Conjunctivitis (PAC)
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country

CHAPTER 6: ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug stores & Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: ALLERGIC CONJUNCTIVITIS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Ajanta Pharma Limited
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Akron Operating Company LLC
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Alembic Pharmaceuticals Ltd.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Bausch Health Companies Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Cipla Ltd
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Grevis Pharmaceutical Private Limited
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Indoco Remedies Ltd.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Jabs Biotech Pvt. Ltd.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 JAWA Pharmaceuticals Pvt. Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Johnson and Johnson
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Novartis AG
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Ocular Therapeutics, Inc.
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Santen Pharmaceuticals Co. Ltd.
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Spectra Vision Care Pvt. Ltd.
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 Sun Pharmaceuticals Industries Ltd
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Teva Pharmaceutical Industries Ltd.
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments

For more information about this report visit https://www.researchandmarkets.com/r/l90m60

Attachment

 
Global Allergic Conjunctivitis Market

Coordonnées